Demant stock holds steady on 2025 revenue and margin gains

Demant (DK0010268440) is anchored by 2025 figures that still define the story for Demant stock: revenue rose 14.3% to DKK 22.4 billion, EBITDA before special items reached DKK 3.9 billion, and free cash flow came to DKK 667 million. Those figures come from the companys 2025 annual report and give investors a clear base for valuation and margin reading.

Revenue up 14.3%

Revenue increased to DKK 22.4 billion in 2025 from DKK 19.6 billion a year earlier, a gain of DKK 2.8 billion that puts the growth rate at 14.3%. EBITDA before special items improved to DKK 3.9 billion from DKK 3.4 billion, while the corresponding margin was 17.4% in 2025 against 17.3% in 2024.

The same report shows a comparison that matters more than the top line alone: free cash flow fell to DKK 667 million from DKK 2.0 billion in 2024, so the stronger earnings profile did not translate into the same cash generation. That split between profit and cash is the main analytical takeaway from the latest reported year.

Cash flow was weaker

Net debt stood at DKK 7.2 billion at 31 December 2025, up from DKK 6.7 billion a year earlier, and that leaves leverage more visible than the revenue headline suggests. For a hearing-aid and diagnostics group, the balance between earnings growth, capital intensity and cash conversion matters as much as unit growth.

Operating profit before special items rose to DKK 2.4 billion in 2025 from DKK 2.1 billion in 2024, which shows the business was still expanding profitability at the operating level. Revenue growth of 14.3% against EBITDA margin stability at 17.4% is the cleanest evidence of that trend.

Margin near 17.4%

The annual report also gives the product mix needed to understand the business: Hearing Care generated DKK 14.6 billion in revenue in 2025, while Diagnostics contributed DKK 4.2 billion. Those segments account for most of Demant's commercial relevance and explain why investors watch both clinic traffic and device demand.

In the same report, Hearing Aids and Hearing Care remain the core of the group, and the size of those lines matters because it drives both recurring service revenue and installed-base economics. A group with DKK 22.4 billion in revenue and DKK 3.9 billion in EBITDA before special items is still being judged on how consistently it can turn sales into cash.

Hearing Care leads

The product side of Demant stock remains tied to hearing solutions rather than a single one-off launch. The companys reported 2025 mix shows why the market usually reads earnings through the lens of both clinical distribution and premium device adoption.

That is also why the 2025 comparison is useful even without a fresh trading-day catalyst: revenue grew 14.3%, EBITDA before special items reached DKK 3.9 billion, and free cash flow was DKK 667 million. Those three dated metrics frame the stock better than any generic sector description.

Trading view matters

Demant shares traded in Copenhagen, and the latest company reporting gives the clearest dated backdrop available in this call. With 2025 revenue at DKK 22.4 billion and net debt at DKK 7.2 billion, the market focus stays on whether the earnings base keeps expanding faster than cash needs.

The stock remains a hearing-care story built on size, margin discipline and conversion, not on a single quarter. For investors, the 2025 report is the reference point until a newer filing sets the next comparison.